SCHEMBL20575605

SCHEMBL20575605

O=C(O)CC(c1cccnc1)S(=O)(=O)c1cccc(NC(=O)c2cccc(NC3=CCCCN3)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.42
ITGB3 P05106 9/20 0.42
ITGAV P06756 9/20 0.42
ITGA2B P08514 8/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGB5 P18084 1/20 0.40
KCNK3 O14649 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SUCNR1 Q9BXA5 2/20 0.38
BRAF P15056 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20574574 0.94 ITGB3 (0.42) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL20575617 0.94 ITGB3 (0.42) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL20575116 0.92 ITGB3 (0.43) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL20574585 0.88 ITGB3 (0.41) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL2838038 0.87 ITGB3 (0.55) ITGB3ITGAVITGA2BITGB1ITGB5
SCHEMBL20575108 0.85 ITGB3 (0.42) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL20575206 0.85 ITGB3 (0.45) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL20575025 0.85 MEN1 (0.41) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL2839127 0.85 ITGB3 (0.54) MEN1KMT2AALDH1A1ITGB3ITGAV
SCHEMBL2834529 0.83 ITGB3 (0.51) MEN1KMT2AALDH1A1ITGB3ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180344803-A1 Methods and Compositions For the Treatment of Proteinuric Diseases THE GENERAL HOSPITAL CORPORATION 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180344803-A1 Methods and Compositions For the Treatment of Proteinuric Diseases ITGB3, PLAUR, PROC MEN1 3989/4885KMT2A 4406/4885ALDH1A1 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.